The US Bio-Chip Market for Pharmaceutical Drug Discovery

Technology, Strategic Alliance, Patent Dispute and Market Update - 2002

Publication Date	May 2002
Publisher	Fuji-Keizai
Product Type	Report
Pages	194
ISBN Number	not applicable
Product Code	FUJ00036

Buy this product or for assistance call +44 20 7060 7474

PDF £660.00$1098 | €739

PRINT £660.00$1098 | €739

FAX Order above formats by FAX

Summary

This report is new market research about the technologies, opportunities and the market for biochips and systems that are being used for accelerating the research processes and capabilities of bio-pharmaceutical drug discovery. This study has found that the total biochip market size in 2001 is about $740 million and may more than triple in revenues, to about $2.47 billion in 2006. The 5-year CAGR is 27.3%. This market includes biochip systems, Lab-on-a chip devices, microarrays, protein chips and other related technologies.

In particular, biochip technologies will continue to help pharma companies. Facing near term product pipeline challenges, Pharma companies have seen their R&D costs explode as their delivery of new drug products have declined. Many of their current high priced $billion -plus blockbuster drugs will reach their patent expirey dates by 2005-2006 and draw competition from generic drug makers. These companies have tried growing through M&As, but their growth has not increased. As a result, pharma companies have increasingly become a source of strong research and financial partners with many of the companies in the biotechnology industry. Pharma companies are motivated to become customers and partners of biochip companies because these companies have technologies that might help the big pharma companies become more productive and deliver more than one product, in a shortened time frame rather than in the current 10-15 year drug development process.

Accelerating the drug making process means turning to modern industrialization of R&D, using genomics and proteomics technologies, and other capabilities that bio-chip companies can provide. This report targets these important issues with interesting and useful findings. This study uses more than 46 figures and tables to illustrate the findings. The wealth of data in the tables summarizes 90 alliance deals, over 375 patents, reviews recent patent disputes, includes categorized lists of microarray products, technologies and 75 web links.

Content

1. Bio-Chip Technology Trends for Drug Discovery
- 1.1 Microarrays and Systems
  - 1.1.1 DNA Microarrays
  - 1.1.2 Lab-on-a-Chip
  - 1.1.3 Protein Arrays
  - 1.1.4 Other Arrays
2. Strategic Alliances and M&As by Companies for Drug Discovery
- 2.1.2 Strategic Alliances
- 2.1.3 Mergers and Acquisitions
3. Bio-Chip Patents
- 3.1 Patent Findings
- 3.2 Tables of Biochip Patents
4. Bio-Chip Patent Disputes: A Few Legal Cases
- 4.1 Affymetrix
  - 4.1.1 Affymetrix v. Incyte Pharmaceuticals and Synteni
  - 4.1.2 Applera Corporation v. Affymetrix
  - 4.1.3 Hyseq,.Inc. v. Affymetrix
- 4.2 Caliper Technologies
  - 4.2.1 Caliper Technologies v. Aclara Biosystems
- 4.3 ID Medical
  - 4.3.1 ID Medical v. Third Wave Technologies
- 4.4 Invitrogen
  - 4.4.1 Invitrogen v. Promega, New England Biolabs and Display Systems
  - 4.4.2 Invitrogen v. Stratagene
- 4.5 Nanogen
  - 4.5.1 Nanogen v. Motorola
- 4.6 Oxford Gene Technology
  - 4.6.1 Oxford Gene Technology v. Affymetrix
  - 4.6.2 Oxford Gene Technology v. Affymetrix, Abbott Labs, Roche Holding, Nanogen and three others
5. Applied Bio-Chip Status for Drug Discovery
- 5.1 Biochip Status
  - 5.1.1 Microarray Systems
  - 5.1.2 Planer cDNA or Oligo Microarray
  - 5.1.3 Microfluidic Array or Lab-on-a-Chip
  - 5.1.4 Protein Chip
  - 5.1.5 Other Array
  - 5.1.6 Array Technology Platform
- 5.2 The Vendors
6. The Bio-Chip Market and Future Outlook
- 6.1 Bio-Chip Market Trends for Drug Discovery R&D
- 6.2 Bio-Chip Market Size by Segment - 2001-2006
- 6.3 Bio-Chip Companies
  - 6.3.1 Target Identification Genomic Technologies
  - 6.3.2 Protein Chip
  - 6.3.3 Protein Databases
  - 6.3.4 Target Validation
  - 6.3.5 Drug Lead Screening
  - 6.3.6 Preclinical Development
  - 6.3.7 Phase 1-3 Clinical Development & Diagnostics
- 6.4 Map of New Players
7. Activities of Leading Bio-Chip Firms for Biopharmaceutical R&D
- 7.1 Bio-Chip Systems
  - 7.1.1 Affymetrix, Inc.
  - 7.1.2 Agilent Technologies, Inc.
  - 7.1.3 GeneMachines, Inc.
  - 7.1.4 Nanogen, Inc.
  - 7.1.5 Motorola Life Sciences
- 7.2 Microarrays
  - 7.2.1 BD Biosciences Clontech
  - 7.2.2 Xeotron Corporation
- 7.3 Lab-on-a-Chip
  - 7.3.1 ACLARA BioSciences, Inc.
  - 7.3.2 Caliper Technologies Corporation
  - 7.3.3 Cepheid, Inc.
  - 7.3.4 Fluidigm Corporation
  - 7.3.5 Nanostream, Inc.
- 7.4 Protein Arrays
  - 7.4.1 Ciphergen Biosystems, Inc.
  - 7.4.2 Phylos, Inc.
  - 7.4.3 Zyomyx, Inc.
- 7.5 Others
  - 7.5.1 Burstein Technologies, Inc.
  - 7.5.2 Illumina, Inc.
  - 7.5.3 Molecular Staging, Inc.
8. Conclusions and New Opportunities
- 8.1 Top 10 Findings of the Hot Developments
  - 8.1.1 Arrays Gaining More Spots
  - 8.1.2 Longer Oligos and cDNAs
  - 8.1.3 Multiplex Arraying
  - 8.1.4 Consolidation in the Pre-Made Microarray Business
  - 8.1.5 Microfluidics Using CD-ROM Technology.
  - 8.1.6 New Reporter Materials Support Denser Microarrays
  - 8.1.7 Electronic Arrays Look Promising.
  - 8.1.8 Protein Chips For The Hot Proteomics Field
  - 8.1.9 Reagents Growing In Importance For In-House Array Makers
  - 8.1.10 Open Systems Trend
- 8.2 Conclusion
9. Appendix 1 - Bioscience Glossary
List of Tables
- Table 1. Definition of Deals
- Table 2. Definition of Technology Category
- Table 3. Summary of Alliances by Category 3Q'00-1Q'02
- Table 4. Summary of Alliances by Technology
- Table 5. Bio-Chip Strategic Alliances (n=90), Sorted by Category
- Table 6. Summary of 'Microarray' Biochip Patents
- Table 7. Summary of 'Lab-on-a-chip/ Microfluidics' Biochip Patents
- Table 8. Summary of 'Other Arrays' Biochip Patents
- Table 9. Summary of 'Protein Chip' Biochip Patents
- Table 10. Key US Microarray Patents (n = 196) by Patent Holder
- Table 11. Key US Lab-on-a-Chip/Microfluidics Patents (n = 148) by Patent Holder
- Table 12. Key US Protein Chip Patents (n = 12) by Patent Holder
- Table 13. Key US "Other Array" Bio-chip Patents (n = 23) by Patent Holder
- Table 14. Key International Patents (n=11) by Patent Holder
- Table 15. Summary of Bio-Chip-based Patent Disputes, 1999-2002
- Table 16. Companies and Applied Biochip Status (n=57)
- Table 17. Total Size of Bio-Chips Market 2001-2006
- Table 18. Total Bio-Chip Market Segments by Percent Market Share
- Table 19. Bio-Chip Segments by Revenues ($M)
- Table 20. Key Bio-Chip Companies
- Table 21. New Players, Ventures and Products
- Table 22. Multiplex Arraying Technology
List of Figures
- Figure 1. Bio-Chip Vendor Market
- Figure 2. Typical Affymetrix GeneChip(tm) System
- Figure 3. Typical Spotted Microarray Result
- Figure 4. GeneMachines OmniGrid Accent Arrayer
- Figure 5. Low-Cost Manual Glass Slide Arrayer
- Figure 6. Agilent DNA and Protein LabChips and Instrument
- Figure 7. Ciphergen's ProteinChip Reader
- Figure 8. PharmaSeq Microtransponder
- Figure 9. Summary of Alliances by Category 3Q'00-1Q'02
- Figure 10. Summary of Alliances by Technology
- Figure 11. Microarray Strategic Alliances by Quarter: 3Q00 - 1Q02
- Figure 12. Caliper Technologies AMS 90SE
- Figure 13. Estimated Total Bio-Chips Market Size by Revenues
- Figure 14. Estimated Total Bio-Chips Market Size by Segment Revenues, 2001-2006
- Figure 15. Comparison of Segment Market Shares for the Bio-Chips Market, 2001 and 2006
- Figure 16. Estimated Market Size by 'DNA Microarray' Segment Revenues, 2001-2006
- Figure 17. Estimated Market Size by 'DNA Microarray Equipment Systems' Segment Revenues, 2001-2006
- Figure 18. Estimated Market Size by 'Lab-on-a-Chip/ Microfluidics' Segment Revenues, 2001-2006
- Figure 19. Estimated Market Size by 'Protein Chips' Segment Revenues, 2001-2006
- Figure 20. Estimated Market Size by 'Protein Chip Equipment' Segment Revenues, 2001-2006
- Figure 21. Estimated Market Size by 'Other Bio-Chips' Segment Revenues, 2001-2006
- Figure 22. Burstein's BioCompact Disc(tm)
- Figure 23. Nanogen NanoChip(tm)
- Figure 24. Nanogen Molecular Biology Workstation
- Figure 25. Zyomyx Biochip for Protein R&D